FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201230444> ?p ?o ?g. }

• W3201230444 abstract "<h3>Introduction</h3> Vedolizumab (VDZ) is a humanised monoclonal IgG-1 antibody that is used in the treatment of inflammatory bowel disease (IBD). Unlike with anti-TNF therapy the benefit of therapeutic drug monitoring (TDM) of VDZ remains debatable. A number of trials have suggested that VDZ trough levels post induction of >18–20 μg/ml are associated with better clinical outcomes.^{1 2} However, data regarding levels in the maintenance phase is less convincing but likely to be lower.¹ Real-world data is lacking, and the use of Vedolizumab drug monitoring is not widely used outside tertiary centres. The aim of this study was to evaluate our current practice at a busy London district general hospital. <h3>Methods</h3> A retrospective study of all patients undergoing VDZ TDM at our unit between July 2017 and December 2019. Data collected included indication and timing of level, value and whether the level resulted in a change in management. <h3>Results</h3> 67 patients were established on VDZ between July 2017 and December 2019. 15 patients (22.4%) had VDZ levels performed with 4 patients undergoing more than one level during this time giving a total of 22 levels performed. Levels were undertaken in the majority of patients for secondary loss of response (LOR) (16/22). A small number were taken during maintenance (4/22), post induction (1/22), and after recapturing response (1/22). Out of the 22 drug levels analysed, 10 (45.5%) were classified as trough levels (within 1 week of a VDZ infusion). Trough levels ranged between 5 μg/ml and 32.7 μg/ml with a median of 15.8 μg/ml. We used a cut-off of 18 μg/ml when interpreting levels. All trough levels taken were performed due to LOR. 6 (60%) levels taken in 4 patients were <18 μg/ml with the remaining 4 levels ≥18 μg/ml. The outcomes of the 4 patients who had sub-therapeutic trough levels were analysed. 2 patients recaptured response after either a course of corticosteroids or optimising 5-ASA therapy. 2 were switched to other therapeutic options (Infliximab and Ustekinumab). A further 3 non-trough levels (in 2 patients) analysed were sub-therapeutic. 1 recaptured response after optimisation and 1 responded to a 3 month period of escalated 4-weekly VDZ therapy. All patients with levels ≥18 μg/ml have continued VDZ therapy with good response. <h3>Conclusions</h3> In our real-world setting, using a cut-off of <18 μg/ml for levels carried out in LOR is helpful in identifying the need to either escalate/optimise or switch agent. However, VDZ levels are being underutilised and are only being taken as trough in 45.5% of patients. There remains uncertainty as to how maintenance levels should be interpreted and national guidance after more studies would be welcome. <h3>References</h3> Papamichael K, Cheifetz A, Melmed G, <i>et al</i>. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> 2019;<b>17</b>:1655–1668. Ward M, Sparrow M and Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therapeutics Advances in Gastroenterology. 2018:11;1–10." @default.
• W3201230444 created "2021-09-27" @default.
• W3201230444 creator A5002367273 @default.
• W3201230444 creator A5032428313 @default.
• W3201230444 creator A5045039026 @default.
• W3201230444 creator A5063847862 @default.
• W3201230444 creator A5080527263 @default.
• W3201230444 date "2021-01-01" @default.
• W3201230444 modified "2023-10-14" @default.
• W3201230444 title "P149 Therapeutic drug monitoring of Vedolizumab for patients with inflammatory bowel disease: real world experience" @default.
• W3201230444 doi "https://doi.org/10.1136/gutjnl-2020-bsgcampus.224" @default.
• W3201230444 hasPublicationYear "2021" @default.
• W3201230444 type Work @default.
• W3201230444 sameAs 3201230444 @default.
• W3201230444 citedByCount "0" @default.
• W3201230444 crossrefType "proceedings-article" @default.
• W3201230444 hasAuthorship W3201230444A5002367273 @default.
• W3201230444 hasAuthorship W3201230444A5032428313 @default.
• W3201230444 hasAuthorship W3201230444A5045039026 @default.
• W3201230444 hasAuthorship W3201230444A5063847862 @default.
• W3201230444 hasAuthorship W3201230444A5080527263 @default.
• W3201230444 hasBestOaLocation W32012304441 @default.
• W3201230444 hasConcept C126322002 @default.
• W3201230444 hasConcept C167135981 @default.
• W3201230444 hasConcept C2776207728 @default.
• W3201230444 hasConcept C2776694085 @default.
• W3201230444 hasConcept C2778260677 @default.
• W3201230444 hasConcept C2778283404 @default.
• W3201230444 hasConcept C2779134260 @default.
• W3201230444 hasConcept C2780035454 @default.
• W3201230444 hasConcept C2780272996 @default.
• W3201230444 hasConcept C2909675724 @default.
• W3201230444 hasConcept C2911091166 @default.
• W3201230444 hasConcept C31785415 @default.
• W3201230444 hasConcept C71924100 @default.
• W3201230444 hasConcept C90924648 @default.
• W3201230444 hasConcept C98274493 @default.
• W3201230444 hasConceptScore W3201230444C126322002 @default.
• W3201230444 hasConceptScore W3201230444C167135981 @default.
• W3201230444 hasConceptScore W3201230444C2776207728 @default.
• W3201230444 hasConceptScore W3201230444C2776694085 @default.
• W3201230444 hasConceptScore W3201230444C2778260677 @default.
• W3201230444 hasConceptScore W3201230444C2778283404 @default.
• W3201230444 hasConceptScore W3201230444C2779134260 @default.
• W3201230444 hasConceptScore W3201230444C2780035454 @default.
• W3201230444 hasConceptScore W3201230444C2780272996 @default.
• W3201230444 hasConceptScore W3201230444C2909675724 @default.
• W3201230444 hasConceptScore W3201230444C2911091166 @default.
• W3201230444 hasConceptScore W3201230444C31785415 @default.
• W3201230444 hasConceptScore W3201230444C71924100 @default.
• W3201230444 hasConceptScore W3201230444C90924648 @default.
• W3201230444 hasConceptScore W3201230444C98274493 @default.
• W3201230444 hasLocation W32012304441 @default.
• W3201230444 hasOpenAccess W3201230444 @default.
• W3201230444 hasPrimaryLocation W32012304441 @default.
• W3201230444 hasRelatedWork W2885490300 @default.
• W3201230444 hasRelatedWork W2911547898 @default.
• W3201230444 hasRelatedWork W3000486757 @default.
• W3201230444 hasRelatedWork W3000635626 @default.
• W3201230444 hasRelatedWork W3092454324 @default.
• W3201230444 hasRelatedWork W3138793908 @default.
• W3201230444 hasRelatedWork W3172730146 @default.
• W3201230444 hasRelatedWork W3201230444 @default.
• W3201230444 hasRelatedWork W4327739650 @default.
• W3201230444 hasRelatedWork W4383683847 @default.
• W3201230444 isParatext "false" @default.
• W3201230444 isRetracted "false" @default.
• W3201230444 magId "3201230444" @default.
• W3201230444 workType "article" @default.